Vaccine · Immune activation, directed at hepatitis B virus surface antigen · developed by Brii Biosciences
BRII-179 (VBI-2601) is given by intramuscular injection, sometimes together with interferon alpha, in studies of chronic hepatitis B virus infection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06491563 | Phase 2 | For Treatment of Chronic Hepatitis B Virus Infection | Completed | VIR |
| NCT04749368 | Phase 2 | Hepatitis B, Chronic | Completed | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
For Treatment of Chronic Hepatitis B Virus InfectionHepatitis B, Chronic
Updated Nov 1, 2026.